When Does a Treatment Effect Really Stop? Exploration of Different Methods for Modelling Treatment Waning

When Does a Treatment Effect Really Stop? Exploration of Different Methods for Modelling Treatment Waning

  • ISPOR Washington 2022
  • Sep 2022
Adoption of Piecewise Modelling: A Review of NICE Health Technology Appraisals in Oncology

Adoption of Piecewise Modelling: A Review of NICE Health Technology Appraisals in Oncology

  • ISPOR Washington 2022
  • Sep 2022
Healthcare Resource Use of People who use Illicit Opioids in England: A Retrospective Cohort Study Using Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES)

Healthcare Resource Use of People who use Illicit Opioids in England: A Retrospective Cohort Study Using Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES)

  • ISPOR Virtual Europe 2021
  • Sep 2022
Capturing The Value Of Potentially Curative Oncology Therapies: Lessons From The Use And Acceptance Of Cure Modelling Assumptions In NICE Technology Appraisals

Capturing The Value Of Potentially Curative Oncology Therapies: Lessons From The Use And Acceptance Of Cure Modelling Assumptions In NICE Technology Appraisals

  • ISPOR Virtual Europe 2021
  • Sep 2022
Orphan Drug Compassionate Use Programmes: Impact on Reimbursement Decisions in France, Germany and England

Orphan Drug Compassionate Use Programmes: Impact on Reimbursement Decisions in France, Germany and England

  • ISPOR Virtual Europe 2021
  • Sep 2022
When Does a Treatment Effect Really Stop? Exploration of Different Methods for Modelling Treatment Waning

When Does a Treatment Effect Really Stop? Exploration of Different Methods for Modelling Treatment Waning

  • ISPOR US 2022
  • Jun 2022
Adoption of Piecewise Modelling: A Review of NICE Health Technology Appraisals in Oncology

Adoption of Piecewise Modelling: A Review of NICE Health Technology Appraisals in Oncology

  • ISPOR US 2022
  • Jun 2022
Investigating Potential Market Failure with Curative Cell and Gene Therapies

Investigating Potential Market Failure with Curative Cell and Gene Therapies

  • ISPOR Milan 2020
  • Feb 2021
Orphan Drug Compassionate Use Programmes: Scale of Use and Association with Regulatory and Reimbursement Decisions in France, Germany and the UK

Orphan Drug Compassionate Use Programmes: Scale of Use and Association with Regulatory and Reimbursement Decisions in France, Germany and the UK

  • ISPOR Milan 2020
  • Feb 2021
Probabilistic Cost-Effectiveness Results and Managed Access Agreements: A Review of Therapies Entering the Cancer Drugs Fund in England

Probabilistic Cost-Effectiveness Results and Managed Access Agreements: A Review of Therapies Entering the Cancer Drugs Fund in England

  • ISPOR Milan 2020
  • Feb 2021
Approaches to the Collection of Utility Values for Rare Diseases: A Cross-Country Comparison

Approaches to the Collection of Utility Values for Rare Diseases: A Cross-Country Comparison

  • ISPOR Milan 2020
  • Feb 2021
Trends in Patient-Focused Presentations at Scientific Congresses: A European Rheumatology Congress Case Study

Trends in Patient-Focused Presentations at Scientific Congresses: A European Rheumatology Congress Case Study

  • ISMPP EU 2020
  • Jan 2020
Loading